{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:36:10Z","timestamp":1785796570546,"version":"3.56.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Celltrion, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40123-025-01197-w","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T09:27:51Z","timestamp":1756459671000},"page":"2769-2783","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-Term Efficacy and Safety of CT-P42 in Patients with Diabetic Macular Edema: 52-Week Results from a Phase 3 Randomized Clinical Trial"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04739306","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"David M.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Veselovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslav","family":"Veith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andras","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobhana","family":"Mange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi Kanta","family":"Mondal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Romanczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladislav","family":"Janco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo\u017cena","family":"Romanowska-Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Eremina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslava","family":"Dusova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Sagong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunghyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YunJu","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngmin","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dain","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyejin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo-Eduardo","family":"Stanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"1197_CR1","doi-asserted-by":"publisher","first-page":"2156273","DOI":"10.1155\/2016\/2156273","volume":"2016","author":"P Romero-Aroca","year":"2016","unstructured":"Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R. Diabetic macular edema pathophysiology: vasogenic versus inflammatory. J Diabetes Res. 2016;2016:2156273. https:\/\/doi.org\/10.1155\/2016\/2156273.","journal-title":"J Diabetes Res"},{"key":"1197_CR2","doi-asserted-by":"publisher","unstructured":"R\u00fcbsam A, Parikh S, Fort PE. Role of inflammation in diabetic retinopathy. Int J Mol Sci. 2018;19(4). https:\/\/doi.org\/10.3390\/ijms19040942.","DOI":"10.3390\/ijms19040942"},{"key":"1197_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.phrs.2015.11.003","volume":"103","author":"S Fogli","year":"2016","unstructured":"Fogli S, Mogavero S, Egan CG, Del Re M, Danesi R. Pathophysiology and pharmacological targets of VEGF in diabetic macular edema. Pharmacol Res. 2016;103:149\u201357. https:\/\/doi.org\/10.1016\/j.phrs.2015.11.003.","journal-title":"Pharmacol Res"},{"key":"1197_CR4","doi-asserted-by":"publisher","unstructured":"Noma H, Yasuda K, Shimura M. Involvement of cytokines in the pathogenesis of diabetic macular edema. Int J Mol Sci. 2021;22(7). https:\/\/doi.org\/10.3390\/ijms22073427.","DOI":"10.3390\/ijms22073427"},{"issue":"2","key":"1197_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171\u201385. https:\/\/doi.org\/10.1007\/s10456-011-9249-6.","journal-title":"Angiogenesis"},{"issue":"11","key":"1197_CR6","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","volume":"121","author":"JF Korobelnik","year":"2014","unstructured":"Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247\u201354. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.006.","journal-title":"Ophthalmology"},{"key":"1197_CR7","unstructured":"European Medicines Agency. Eylea summary of product characteristics, 2017. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eylea-epar-product-information_en.pdf. Accessed 17 Jul 2025."},{"key":"1197_CR8","unstructured":"US Food and Drug Administration. Eylea prescribing information, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125387lbl.pdf. Accessed 27 Jul 2025."},{"issue":"10","key":"1197_CR9","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","volume":"122","author":"DM Brown","year":"2015","unstructured":"Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology. 2015;122(10):2044\u201352. https:\/\/doi.org\/10.1016\/j.ophtha.2015.06.017.","journal-title":"Ophthalmology"},{"issue":"11","key":"1197_CR10","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","volume":"123","author":"JS Heier","year":"2016","unstructured":"Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology. 2016;123(11):2376\u201385. https:\/\/doi.org\/10.1016\/j.ophtha.2016.07.032.","journal-title":"Ophthalmology"},{"issue":"13","key":"1197_CR11","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"JA Wells","year":"2015","unstructured":"Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193\u2013203. https:\/\/doi.org\/10.1056\/NEJMoa1414264.","journal-title":"N Engl J Med"},{"issue":"6","key":"1197_CR12","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","volume":"123","author":"JA Wells","year":"2016","unstructured":"Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2016.02.022.","journal-title":"Ophthalmology"},{"issue":"4","key":"1197_CR13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000458539","volume":"237","author":"U Schmidt-Erfurth","year":"2017","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the european society of retina specialists (EURETINA). Ophthalmologica. 2017;237(4):185\u2013222. https:\/\/doi.org\/10.1159\/000458539.","journal-title":"Ophthalmologica"},{"issue":"1","key":"1197_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s40123-023-00829-3","volume":"13","author":"S Donati","year":"2024","unstructured":"Donati S, Yang CH, Xu X, et al. Intravitreal aflibercept for the treatment of diabetic macular edema in routine clinical practice: results from the 24-month AURIGA observational study. Ophthalmol Ther. 2024;13(1):161\u201378. https:\/\/doi.org\/10.1007\/s40123-023-00829-3.","journal-title":"Ophthalmol Ther"},{"issue":"13","key":"1197_CR15","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1038\/s41433-023-02409-y","volume":"37","author":"S Sivaprasad","year":"2023","unstructured":"Sivaprasad S, Ghanchi F, Kelly SP, et al. Evaluation of care with intravitreal aflibercept treatment for UK patients with diabetic macular oedema: DRAKO study 24-month real-world outcomes. Eye (Lond). 2023;37(13):2753\u201360. https:\/\/doi.org\/10.1038\/s41433-023-02409-y.","journal-title":"Eye (Lond)"},{"key":"1197_CR16","doi-asserted-by":"publisher","DOI":"10.2196\/56741","volume":"10","author":"K Choi","year":"2024","unstructured":"Choi K, Park SJ, Yoon H, et al. Patient-centered economic burden of diabetic macular edema: retrospective cohort study. JMIR Public Health Surveill. 2024;10:e56741. https:\/\/doi.org\/10.2196\/56741.","journal-title":"JMIR Public Health Surveill"},{"issue":"3","key":"1197_CR17","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1177\/11206721211033480","volume":"32","author":"P Gascon","year":"2022","unstructured":"Gascon P, Borget I, Comet A, Carton L, Matonti F, Dupont-Benjamin L. Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study). Eur J Ophthalmol. 2022;32(3):1702\u20139. https:\/\/doi.org\/10.1177\/11206721211033480.","journal-title":"Eur J Ophthalmol"},{"issue":"10","key":"1197_CR18","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.ophtha.2018.04.007","volume":"125","author":"TY Wong","year":"2018","unstructured":"Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology. 2018;125(10):1608\u201322. https:\/\/doi.org\/10.1016\/j.ophtha.2018.04.007.","journal-title":"Ophthalmology"},{"issue":"2","key":"1197_CR19","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40123-023-00672-6","volume":"12","author":"OA Sam-Oyerinde","year":"2023","unstructured":"Sam-Oyerinde OA, Patel PJ. Real-world outcomes of anti-VEGF therapy in diabetic macular oedema: barriers to treatment success and implications for low\/lower-middle-income countries. Ophthalmol Ther. 2023;12(2):809\u201326. https:\/\/doi.org\/10.1007\/s40123-023-00672-6.","journal-title":"Ophthalmol Ther"},{"issue":"4","key":"1197_CR20","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.survophthal.2022.01.009","volume":"67","author":"JHB Im","year":"2022","unstructured":"Im JHB, Jin YP, Chow R, Yan P. Prevalence of diabetic macular edema based on optical coherence tomography in people with diabetes: a systematic review and meta-analysis. Surv Ophthalmol. 2022;67(4):1244\u201351. https:\/\/doi.org\/10.1016\/j.survophthal.2022.01.009.","journal-title":"Surv Ophthalmol"},{"issue":"11","key":"1197_CR21","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","volume":"128","author":"ZL Teo","year":"2021","unstructured":"Teo ZL, Tham YC, Yu M, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021;128(11):1580\u201391. https:\/\/doi.org\/10.1016\/j.ophtha.2021.04.027.","journal-title":"Ophthalmology"},{"issue":"3","key":"1197_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.2004","volume":"7","author":"MJ Hossain","year":"2024","unstructured":"Hossain MJ, Al-Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: early detection should be focused. Health Sci Rep. 2024;7(3):e2004. https:\/\/doi.org\/10.1002\/hsr2.2004.","journal-title":"Health Sci Rep"},{"issue":"2","key":"1197_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-020-01256-5","volume":"80","author":"H Kim","year":"2020","unstructured":"Kim H, Alten R, Avedano L, et al. The future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases. Drugs. 2020;80(2):99\u2013113. https:\/\/doi.org\/10.1007\/s40265-020-01256-5.","journal-title":"Drugs"},{"key":"1197_CR24","unstructured":"US Food and Drug Administration. FDA approves first interchangeable biosimilars to Eylea to treat macular degeneration and other eye conditions. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-first-interchangeable-biosimilars-eylea-treat-macular-degeneration-and-other-eye#:~:text=FDA%20approved%20Yesafili%20(aflibercept%2Djbvf,vessel%20growth%20within%20the%20eye. Accessed 6 Nov 2024."},{"issue":"1","key":"1197_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40942-021-00343-3","volume":"8","author":"M Kapur","year":"2022","unstructured":"Kapur M, Nirula S, Naik MP. Future of anti-VEGF: biosimilars and biobetters. Int J Retina Vitreous. 2022;8(1):2. https:\/\/doi.org\/10.1186\/s40942-021-00343-3.","journal-title":"Int J Retina Vitreous."},{"key":"1197_CR26","unstructured":"Australian Register of Therapeutic Goods. Australian product information Eydenzelt\u00ae (aflibercept). 2025. https:\/\/www.tga.gov.au\/resources\/artg?keywords=eydenzelt&f%5B0%5D=artg_type%3AMedicine. Accessed 27 May 2025."},{"key":"1197_CR27","unstructured":"Ministry of Food and Drug Safety. Aidenzelt prefilled syringe. https:\/\/nedrug.mfds.go.kr\/pbp\/CCBBB01\/getItemDetailCache?cacheSeq=202401327aupdateTs2024-06-19%2016:23:00.054976b. Accessed 28 Feb 2025."},{"key":"1197_CR28","unstructured":"ClinicalTrials.gov. Study to compare efficacy and safety of CT-P42 in comparison with eylea in patients with diabetic macular edema. https:\/\/clinicaltrials.gov\/study\/NCT04739306. Accessed 6 Nov 2024."},{"issue":"12","key":"1197_CR29","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.oret.2024.06.013","volume":"8","author":"S Wolf","year":"2024","unstructured":"Wolf S, Stanga PE, Veselovsky M, et al. Biosimilar candidate CT-P42 in diabetic macular edema: 24-week results from a randomized, active-controlled, phase III study. Ophthalmol Retina. 2024;8(12):1163\u201373 https:\/\/doi.org\/10.1016\/j.oret.2024.06.013.","journal-title":"Ophthalmol Retina."},{"issue":"7329","key":"1197_CR30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Antithrombotic Trialists' Collaboration","year":"2002","unstructured":"Antithrombotic Trialists\u2019 Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71\u201386. https:\/\/doi.org\/10.1136\/bmj.324.7329.71.","journal-title":"BMJ"},{"key":"1197_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","volume":"238","author":"DM Brown","year":"2022","unstructured":"Brown DM, Emanuelli A, Bandello F, et al. KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema. Am J Ophthalmol. 2022;238:157\u201372. https:\/\/doi.org\/10.1016\/j.ajo.2022.01.004.","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"1197_CR32","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1001\/jamaophthalmol.2024.3458","volume":"142","author":"SB Bressler","year":"2024","unstructured":"Bressler SB, Barve A, Ganapathi PC, et al. Aflibercept biosimilar MYL-1701P vs reference aflibercept in diabetic macular edema: the INSIGHT randomized clinical trial. JAMA Ophthalmol. 2024;142(10):952\u201360. https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.3458.","journal-title":"JAMA Ophthalmol"},{"key":"1197_CR33","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ajo.2023.07.012","volume":"260","author":"CC Wykoff","year":"2024","unstructured":"Wykoff CC, Garweg JG, Regillo C, et al. KESTREL and KITE Phase 3 studies: 100-week results with brolucizumab in patients with diabetic macular edema. Am J Ophthalmol. 2024;260:70\u201383. https:\/\/doi.org\/10.1016\/j.ajo.2023.07.012.","journal-title":"Am J Ophthalmol"},{"issue":"10326","key":"1197_CR34","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/s0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2024","unstructured":"Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741\u2013755. https:\/\/doi.org\/10.1016\/s0140-6736(22)00018-6.","journal-title":"Lancet"},{"issue":"9","key":"1197_CR35","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1001\/archophthalmol.2012.1107","volume":"130","author":"SB Bressler","year":"2012","unstructured":"Bressler SB, Qin H, Beck RW, et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol. 2012;130(9):1153\u201361. https:\/\/doi.org\/10.1001\/archophthalmol.2012.1107.","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"1197_CR36","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1001\/jamaophthalmol.2019.1963","volume":"137","author":"NM Bressler","year":"2019","unstructured":"Bressler NM, Odia I, Maguire M, et al. association between change in visual acuity and change in central subfield thickness during treatment of diabetic macular edema in participants randomized to aflibercept, bevacizumab, or ranibizumab: a post hoc analysis of the protocol T randomized clinical trial. JAMA Ophthalmol. 2019;137(9):977\u201385. https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.1963.","journal-title":"JAMA Ophthalmol"},{"issue":"19","key":"1197_CR37","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1001\/jama.2019.5790","volume":"321","author":"CW Baker","year":"2019","unstructured":"Baker CW, Glassman AR, Beaulieu WT, et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical Trial. JAMA. 2019;321(19):1880\u201394. https:\/\/doi.org\/10.1001\/jama.2019.5790.","journal-title":"JAMA"},{"issue":"17","key":"1197_CR38","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.1073\/pnas.172398299","volume":"99","author":"J Holash","year":"2002","unstructured":"Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99(17):11393\u20138. https:\/\/doi.org\/10.1073\/pnas.172398299.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1197_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40942-016-0026-y","volume":"2","author":"JR de Oliveira Dias","year":"2016","unstructured":"de Oliveira Dias JR, de Andrade GC, Novais EA, Farah ME, Rodrigues EB. Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept. Int J Retina Vitreous. 2016;2:3. https:\/\/doi.org\/10.1186\/s40942-016-0026-y.","journal-title":"Int J Retina Vitreous"},{"key":"1197_CR40","doi-asserted-by":"publisher","unstructured":"Moon BH, Kim Y, Kim SY. Twenty years of anti-vascular endothelial growth factor therapeutics in neovascular age-related macular degeneration treatment. Int J Mol Sci. 2023;24(16). https:\/\/doi.org\/10.3390\/ijms241613004.","DOI":"10.3390\/ijms241613004"},{"issue":"10","key":"1197_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0311484","volume":"19","author":"T Hirano","year":"2024","unstructured":"Hirano T, Murata T, Nakao S, et al. Optimization of individualized faricimab dosing for patients with diabetic macular edema: protocol for the SWAN open-label, single-arm clinical trial. PLoS ONE. 2024;19(10):e0311484. https:\/\/doi.org\/10.1371\/journal.pone.0311484.","journal-title":"PLoS ONE"},{"key":"1197_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.917814","volume":"13","author":"E Allocati","year":"2022","unstructured":"Allocati E, Godman B, Gobbi M, Garattini S, Banzi R. Switching among biosimilars: a review of clinical evidence. Front Pharmacol. 2022;13:917814. https:\/\/doi.org\/10.3389\/fphar.2022.917814.","journal-title":"Front Pharmacol"},{"key":"1197_CR43","unstructured":"European Medicines Agency. Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf. Accessed 27 May 2025."},{"key":"1197_CR44","unstructured":"IQVIA. The impact of biosimilar competition in Europe. https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/white-papers\/the-impact-of-biosimilar-competition-in-europe-2023.pdf. Accessed 3 Oct 2024."},{"key":"1197_CR45","unstructured":"IQVIA. Global medicine spending and usage trends: outlook to 2025. https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/institute-reports\/global-medicine-spending-and-usage-trends-outlook-for-2025\/iqvia-institute-global-medicines-and-usage-trends-to-2025-0421-forweb.pdf. Accessed 3 Oct 2024."}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01197-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01197-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01197-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:42:21Z","timestamp":1760715741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01197-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1197"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01197-w","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"David M. Brown reports consultancy fees\/honoraria from AbbVie, Alexion, Annexon, Apellis, Bayer, Biogen, Boehringer Ingelheim, Celltrion, Clearside, Heidelberg, Kodiak, Kowa, Merit, Novartis, Ocular Therapeutix, Ocuphire, OPTOS, Ray Therapeutics, Regeneron, RetinAI, Samsung Bioepis, SciNeuro, Senju, Stealth, THEA, Topcon, Voiant, and Xequel; institutional research grants from AffaMed, Alcon, Alexion, Allergan, Amgen, Annexon, Apellis, Astellas, Bayer, BIRC, Boehringer Ingelheim, Chengdu Kanghong, Clearside, Eyebiotech, EyePoint, Roche, Gemini, Genentech, Graybug Vision, Gyroscope, Heidelberg, i-Lumen, IONIS, Kodiak, LumiThera, MeiraGTx, Mylan, NGM, Novartis, Ocular Therapeutix, Ocuphire, OcuTerra, Opthea, OPTOS, Outlook Therapeutics, OXULAR, Regeneron, RegenXBio, Rezolute, SamChunDang, Samsung, Sandoz, Santen, SciFluor, Senju, Shanghai Henlius, Stealth, Taiwan Liposome Company, ThromboGenics, Xbrane, and Zeiss; and stock options for Adverum, Clearside, and Ocuphire. Sebastian Wolf reports consultancy fees from BCN Peptides, Celltrion, La Science, Novartis, Oculis, and Priothera. Andras Papp is a consultant for Akceso Advisors, Apobiologix\/Apotex, Bayer, Formycon, Novartis, Ocular Therapeutix, and Teva; has received travel grants from Novartis and Roche; and his department has been involved in the conduct of several studies sponsored by Allergan, Altos Biologics, Alvotech, Amgen, Bayer, Bioeq, Celltrion, Inc., Chengdu Kanghong, Clearside Biomedical, Eyebiotech Ltd, Genentech, Intas Pharmaceuticals, Novartis, Oculis, Ophthea, Ophthotech\/Iveric Bio, Qilu, Regeneron, Roche, Sam Chun Dang Pharm. Co. Ltd., Samsung Bioepis, Shanghai Henlius Biotech, Inc., ThromboGenics, and Xbrane. Rohan Chauhan has received clinical research grants from Alvotech, Biocon, Intas Biopharma, Lambda Therapeutics, Lupin Ltd, Mylan (part of Viatris), Oculis Pharma, and Reliance Life Sciences. Min Sagong has been a consultant for and receives grant support and lecture fees from Alcon, Allergan\/AbbVie, Bayer, Celltrion, Curacle, Novartis, PharmAbcine, Roche, and Samsung Bioepis; and receives grant support from Alteogen, Kyowa Kirin, Janssen, Johnson & Johnson, Opthea Therapeutics, and Sam Chun Dang. Sunghyun Kim, YunJu Bae, and Suyoung Kim are employees of Celltrion, Inc. and hold stocks and stock options in Celltrion, Inc. Youngmin Bae, Dain Son, Hyejin\u00a0Kang, and Sujin Choi are employees of Celltrion, Inc. Paulo-Eduardo Stanga has a consultancy agreement with Celltrion, Inc. Milan Veselovsky, Miroslav Veith, Shobhana Mange, Lakshmi Kanta Mondal, Dominika Romanczak, Ladislav Janco, Bo\u017cena\u00a0Romanowska-Dixon, Alena Eremina, and Jaroslava Dusova have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was performed in accordance with Good Clinical Practice, the principles of the Declaration of Helsinki, and relevant country-specific regulatory requirements. Independent ethics committees and institutional review boards at each site prospectively approved the study materials (Table  in Supplementary Material), and all patients provided written, informed consent for study participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}